Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Roche’s Evrysdi Approved For SMA, Priced Below Competitors

Oral drug will rival Biogen, Novartis therapies

Executive Summary

Risdiplam’s efficacy across two clinical trials and oral dosing made it a credible threat before its US FDA approval, but its weight-based pricing falls below Biogen’s Spinraza and Novartis’s Zolgensma. 

You may also be interested in...



J&J Jumps On RNA-Based Small Molecules Train In Pact With Remix

Deal Snapshot: The deal, with an upfront payment of $45m, is the latest of several involving large biopharma companies and smaller firms focused on small molecule drugs based on RNA biology.

Biogen Acquires Ionis’ Spinal Muscular Atrophy Candidate As Spinraza Loses Its Shine

The firm has stumped up $60m for Ionis’s preclinical antisense asset in spinal muscular atrophy, a potential successor to the slowing Spinraza, which also faces patent expiry in a few years.

Novartis Can Again Pursue Bigger Zolgensma Market After FDA Lifts OAV-101 Hold

Novartis aims to double the addressable market for its spinal muscular atrophy gene therapy – and catch up to competitors – with the intrathecal version known as OAV-101.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC142751

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel